Patents by Inventor Philipp Kirchhoff
Philipp Kirchhoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11510894Abstract: The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease.Type: GrantFiled: January 25, 2007Date of Patent: November 29, 2022Inventors: John P. Geibel, Philipp Kirchhoff
-
Publication number: 20200345767Abstract: The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease.Type: ApplicationFiled: February 19, 2020Publication date: November 5, 2020Inventors: John P. Geibel, Philipp Kirchhoff
-
Patent number: 10603339Abstract: The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease.Type: GrantFiled: September 21, 2018Date of Patent: March 31, 2020Assignee: YALE UNIVERSITYInventors: John P. Geibel, Philipp Kirchhoff
-
Publication number: 20190240061Abstract: The present invention relates to a ring (1) for implantation in patients receiving stoma having (i) an inner ring (2) suitable for fitting an abdominal wall on its outer circumference having an opening (3) suitable for an abdominal organ to pass through the ring to the exterior side (5) and (ii) a lip seal (4) extending over the interior side (5) of the inner ring (2) to seal the stoma opening for use in abdominal surgery. In addition, the present invention is directed to a method of treatment, comprising the surgical introduction of a ring (1) of the invention into the abdominal wall of a mammal in need of abdominal, preferably stoma surgery.Type: ApplicationFiled: February 7, 2019Publication date: August 8, 2019Inventor: Philipp KIRCHHOFF
-
Patent number: 10278989Abstract: The present invention relates to the use of pharmaceutically acceptable zinc salts, in particular, zinc chloride and zinc acetate, alone or optionally, in combinations with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, including acid secretion in the fundus (by inhibiting vacuolar H+-ATPase or H+/K+-ATPase) and upper body region of the stomach (by inhibiting H+/K+-ATPase), thus raising the pH of gastric juices in rapid fashion and decreasing the duration of stomach acid release during a secretagogue phase. This method is also directed to treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease.Type: GrantFiled: May 22, 2013Date of Patent: May 7, 2019Assignee: YALE UNIVERSITYInventors: John P. Geibel, Philipp Kirchhoff
-
Publication number: 20190022139Abstract: The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease.Type: ApplicationFiled: September 21, 2018Publication date: January 24, 2019Inventors: John P. Geibel, Philipp Kirchhoff
-
Publication number: 20150231175Abstract: The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease.Type: ApplicationFiled: March 4, 2015Publication date: August 20, 2015Inventors: John P. Geibel, Philipp Kirchhoff
-
Patent number: 9034391Abstract: The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease.Type: GrantFiled: July 22, 2008Date of Patent: May 19, 2015Assignee: YALE UNIVERSITYInventors: John P. Geibel, Philipp Kirchhoff
-
Publication number: 20140243588Abstract: The present invention relates to a ring (1) for implantation in patients receiving stoma having (i) an inner ring (2) suitable for fitting an abdominal wall on its outer circumference having an opening (3) suitable for an abdominal organ to pass through the ring to the exterior side (5) and (ii) a lip seal (4) extending over the interior side (5) of the inner ring (2) to seal the stoma opening for use in abdominal surgery. In addition, the present invention is directed to a method of treatment, comprising the surgical introduction of a ring (1) of the invention into the abdominal wall of a mammal in need of abdominal, preferably stoma surgery.Type: ApplicationFiled: October 19, 2012Publication date: August 28, 2014Applicant: UNIVERSITAETSSPITAL BASELInventor: Philipp Kirchhoff
-
Patent number: 8512761Abstract: The present invention relates to the use of pharmaceutically acceptable zinc salts, in particular, zinc chloride and zinc acetate alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2-blocker, cytoprotective agent or a combination of agents as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, including acid secretion in the fundus (by inhibiting vacuolar H+-ATPase or H+/K+-ATPase) and upper body region of the stomach (by inhibiting H+/K+-ATPase), thus raising the pH of gastric juices in rapid fashion and decreasing the duration of stomach acid release during a secretagogue phase. The method is also directed to treating conditions including gastroesophogeal reflux disease, non-erosive reflux disease, Zollinger-Ellison syndrome, ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease.Type: GrantFiled: July 26, 2007Date of Patent: August 20, 2013Assignee: Yale UniversityInventors: John P Geibel, Philipp Kirchhoff
-
Publication number: 20100150861Abstract: The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease.Type: ApplicationFiled: July 22, 2008Publication date: June 17, 2010Applicant: YALE UNIVERSITYInventors: John P. Geibel, Philipp Kirchhoff
-
Publication number: 20090035393Abstract: The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease.Type: ApplicationFiled: January 25, 2007Publication date: February 5, 2009Inventors: John P. Geibel, Philipp Kirchhoff
-
Publication number: 20080038368Abstract: The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease.Type: ApplicationFiled: July 26, 2007Publication date: February 14, 2008Applicant: YALE UNIVERSITYInventors: John Geibel, Philipp Kirchhoff